NAPSA

Across TCGA pan-cancer cohorts, NAPSA mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated NAPSA data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NAPSA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NAPSA expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD and CCRCC are the cancer types where NAPSA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.849	0.346	<.001	31	view →
CCRCC	OS	Quartile	All	0.963	0.781	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

NAPSA–LUAD (OS)

Open the LUAD breakdown →